BLACK DIAMOND THERAPEUTICS I

Black Diamond insider option exercise signals confidence amid a volatile 52‑week low; steady accumulation suggests long‑term faith in its cancer pipeline.

Insider buying by Black Diamond Therapeutics’ director signals confidence amid sharp price dips—potential entry point for long‑term investors.

Raman Prakash’s $1.66 buy of 7,907 Black Diamond Therapeutics shares shows insider confidence amid a “buy‑the‑dip” strategy, hinting at future upside in its genetically‑defined cancer focus.